Patent ID: 7214698

Claim:
A method for treating a disease or condition selected from the group consisting of obesity, insulin resistance; type 2 diabetes mellitus; urinary incontinence and irritable colon, said method comprising administering to a host in need of such treatment a therapeutically effective amount of f a compound of formula I wherein R 1 , R 2 , R 10 , R 11 independently of one another denote a group selected from among hydrogen, halogen, CN, NO 2 , and —NHCXNH 2 or a group selected from among optionally substituted —COR 7 , —COOR 7 , —CONR 7 R 13 , —OR 14 , NR 13 R 15 , C 1 –C 10 -alkyl, C 3 –C 8 -cycloalkyl, —NR 16 CX—R 17 , —NR 18 CX—OR 19 , —NR 20 SO m R 21 , —SO p NR 22 R 23 and —SO q R 24 m, p, q denotes 0, 1 or 2 n denotes 0, 1, 2 or 3 R 3 denotes hydrogen or a group selected from among optionally substituted C 1 –C 10 -alkyl, C 6 –C 10 -aryl, heterocyclyl and C 3 –C 8 -cycloalkyl, —CX—C 1 –C 10 -alkyl and —CX—C 6 –C 14 -aryl, R 4 , R 5 independently of one another denote hydrogen, halogen or optionally substituted C 1 –C 10 -alkyl, or R 4 and R 5 together denote a C 3 –C 8 -alkyl bridge, R 6 denotes a group of formula l,k independently of one another denote 1,2 or 3, R 25 , R 26 independently of one another denote a group selected from among hydrogen, OH, halogen, CN and NO 2 , or a group selected from among optionally substituted C 1 –C 10 -alkyl, C 6 –C 18 -aryl, heteroaryl, heterocyclyl, —CX—R 17 , —OR 14 , NR 13 R 15 , C 3 –C 8 -cycloalkyl —NR 20 SO m R 21 , —SO p NR 22 R 23 , —SO q R 24 , —NR 18 CX—R 19 and —NR 18 CXOR 17 , while R 25 and R 26 cannot simultaneously denote hydrogen, R 8 denotes hydrogen or a group selected from among optionally substituted C 1 –C 10 -alkyl, C 6 –C 18 -aryl, —SO q —C 1 –C 10 -alkyl, —SO q —C 6 –C 14 -aryl, —CX—C 1 –C 10 -alkyl, —CX—C 6 –C 14 -aryl, C 6 –C 10 -aryl, heterocyclyl and C 3 –C 8 -cycloalkyl R 9 denotes hydrogen or a group selected from among optionally substituted C 1 –C 10 -alkyl, C 6 –C 14 -aryl, heteroaryl, C 3 –C 8 -cycloalkyl and heterocycloalkyl, R 12 denotes hydrogen or a group selected from among optionally substituted benzyl, C 1 –C 12 -alkyl and C 6 –C 14 -aryl, R 7 , R 13 , R 15 , R 16 , R 18 , R 20 R 22 , R 23 independently of one another denote hydrogen, or a group selected from among optionally substituted C 1 –C 10 -alkyl, C 6 –C 14 -aryl, heterocyclyl and C 3 –C 8 -cycloalkyl R 14 , R 19 , R 29 independently of one another denote hydrogen or a group selected from among optionally substituted C 1 –C 10 -alkyl, C 6 –C 14 -aryl, C 3 –C 8 -cycloalkyl, heteroaryl, heterocyclyl, —CXNR 13 R 15 and —CXR 7 R 17 denotes a group selected from among C 1 –C 10 -alkyl, C 6 –C 14 -aryl, heterocyclyl, heteroaryl and C 3 –C 8 -cycloalkyl R 21 , R 24 independently denote hydrogen or OH, or a group selected from among optionally substituted N(C 1 –C 10 -alkyl) 2 , N(C 3 –C 8 -cycloalkyl), C 1 –C 10 -alkyl, C 6 –C 14 -aryl, heterocyclyl, heteroaryl and C 3 –C 8 -cycloalkyl and X denotes O, S or NR 29 , or a pharmaceutically acceptable salt thereof.